Aug 13 (Reuters) - Grail Inc ( GRAL ) said on Tuesday it

has cut about 350 existing jobs as the diagnostics company

focuses on the development of its flagship cancer-detection test

Galleri.

The company, which listed its shares on the Nasdaq after

being spun out of gene sequencing machine maker Illumina in

June, is betting on commercial partnerships with health systems,

employers and life insurance companies through Galleri.

"As part of this restructure, we are reducing existing

headcount and planned hires for 2024 by about 30% and

substantially decreasing investment in product programs beyond

Galleri," Grail said in a statement.

The cancer test maker expects these cost reductions to

extend its existing cash runway from the second half of 2026

into 2028 and anticipates reducing its burn in 2025 to $325

million.